IP Library Granted Patent US 10,646,347
Granted Patent B2
US 10,646,347 · App. 15/619,767 · Granted May 12, 2020

Protein delivery with porous metallic structure

Inventors: Jeffrey Welch (Durham, NC); Eric Vanderploeg (Stoneham, MA); Christopher Wilson (Auburndale, MA); John Wozney (Hudson, MA)
Assignee: Bioventus LLC.
A61F2/30767A61L27/06A61L27/227A61L27/427A61L27/56A61L31/14A61F2/28A61L31/16A61L2300/414A61L2430/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,646,347
App. No.
15/619,767
Granted
May 12, 2020
Kind
B2
Abstract

Osteoconductive synthetic bone grafts are provided in which porous metallic matrices are loaded with an osteoinductive protein. In certain embodiments, the grafts include porous ceramic granules deposited within the matrices.

Claims (50)

1. A biocompatible implant, comprising:

a matrix comprising nitinol (Ti—Ni) comprising a plurality of pores, wherein the matrix has a porosity of 58%-68% and the plurality of pores have a mean pore size between 50 and 500 microns; and

an osteoinductive protein;

wherein the pores are randomly distributed throughout the matrix.

2. The biocompatible implant of claim 1 , wherein said osteoinductive protein is bone morphogenic protein (BMP) BMP-GER-NR.

3. The biocompatible implant of claim 1 , wherein said osteoinductive protein is bone morphogenic protein BMP-GER.

4. The biocompatible implant of claim 1 , wherein said osteoinductive protein is bone morphogenic protein BMP-2.

5. The biocompatible implant of claim 1 , wherein said osteoinductive protein is bone morphogenic protein BMP-7.

6. The implant of claim 1 , wherein the atomic ratio of nickel to titanium in said matrix is between 0.96:1 and 1.13:1.

7. The implant of claim 1 , wherein said matrix is characterized by one or more openings with an average diameter of at least 1-2 millimeters.

8. The implant of claim 1 , wherein said matrix is characterized by one or more openings with an average size of from 5 to 10 millimeters.

9. The implant of claim 1 , wherein said matrix is characterized by a single opening having an average size of from 10 to 20 millimeters.

10. A biocompatible implant, comprising:

a matrix comprising Ti—Ni comprising a plurality of pores, wherein the matrix has a porosity of 58%-68% and the pores have a mean pore size between 50 and 500 microns; and

an osteoinductive protein comprising BMP-GER-NR, and

wherein the pores are randomly distributed throughout the matrix.

11. A biocompatible implant, comprising:

a matrix comprising Ti—Ni comprising a plurality of pores, wherein the matrix has a porosity of 58%-68% and the pores have a mean pore size between 50 and 500 microns; and an osteoinductive protein comprising BMP-GER,

wherein the pores are randomly distributed throughout the matrix.

12. A kit comprising the implant of claim 1 .

13. The kit of claim 12 , wherein the osteoinductive protein is lyophilized and provided in a container.

14. A kit comprising the implant of claim 10 .

15. The kit of claim 14 , wherein the osteoinductive protein is lyophilized and provided in a container.

16. A kit comprising the implant of claim 11 .

17. The kit of claim 16 wherein the osteoinductive protein is lyophilized and provided in a container.

18. A method of treating a patient, comprising the steps of:

contacting a bony tissue of the patient with a biocompatible implant, said implant comprising:

a matrix comprising Ti—Ni having a plurality of pores, wherein the matrix has a porosity of 58%-68% and the pores have a mean pore size between 50 and 500 microns; and

an osteoinductive protein,

wherein the pores are randomly distributed throughout the matrix.

19. The biocompatible implant of claim 10 , wherein the matrix further comprises one or more openings having an average size of from 1 to 2 millimeters.

20. The biocompatible implant of claim 11 , wherein the matrix further comprises one or more openings having an average size of from 1 to 2 millimeters.

21. A biocompatible implant, comprising:

a matrix comprising Ti—Ni and a plurality of pores, wherein the matrix has a porosity of 58%-68% and the pores have a mean pore size between 50 and 500 microns;

an osteoinductive protein, and wherein the pores are randomly distributed throughout the matrix; and

a plurality of porous, calcium ceramic granules deposited within an open region of the matrix at a ratio of 150-310 milligrams of granules per cubic centimeter of matrix.

22. The implant of claim 21 , wherein said osteoinductive protein is associated with said granules.

23. The implant of claim 21 , wherein said osteoinductive protein is associated with said matrix.

24. The implant of claim 21 , wherein the atomic ratio of nickel to titanium in said matrix is between 0.96:1 and 1.13:1.

25. The implant of claim 21 , wherein said granules have an average size within the range of 225 to 800 microns.

26. The implant of claim 21 , wherein said matrix is characterized by openings with an average size of 1-2 millimeters.

27. The implant of claim 21 , wherein said calcium ceramic granules comprise calcium deficient hydroxyapatite.

28. The implant of claim 21 , wherein said osteoinductive protein is BMP-GER-NR.

29. The implant of claim 21 , wherein said osteoinductive protein is BMP-GER.

30. The implant of claim 21 , wherein said osteoinductive protein is BMP-2.

31. The implant of claim 21 , wherein said osteoinductive protein is BMP-7.

32. The biocompatible implant of claim 1 , wherein the matrix has a porous structure in which less than 5 vol % of the pores are less than 50 microns in size, more than 75 vol % of the pores are 50-500 microns in size, and the balance of the pores are greater than 500 microns in size.

33. The biocompatible implant of claim 11 , wherein the matrix has a porous structure in which less than 5 vol % of the pores are less than 50 microns in size, more than 75 vol % of the pores are 50-500 microns in size, and the balance of the pores are greater than 500 microns in size.

34. The method of claim 18 , wherein the matrix has a porous structure in which less than 5 vol % of the pores are less than 50 microns in size, more than 75 vol % of the pores are 50-500 microns in size, and the balance of the pores are greater than 500 microns in size.

35. The biocompatible implant of claim 21 , wherein the matrix has a porous structure in which less than 5 vol % of the pores are less than 50 microns in size, more than 75 vol % of the pores are 50-500 microns in size, and the balance of the pores are greater than 500 microns in size.

Assignments (4)
SECURITY INTEREST Recorded Aug 1, 2025
From: BIOVENTUS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071904/0465 →
RELEASE OF SECURITY INTEREST Recorded Aug 1, 2025
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BIOVENTUS LLC
Reel/Frame 071909/0861 →
SECURITY INTEREST Recorded Dec 13, 2019
From: BIOVENTUS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 051272/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2017
From: WELCH, JEFFREY; VANDERPLOEG, ERIC; WILSON, CHRISTOPHER; WOZNEY, JOHN
To: BIOVENTUS, LLC
Reel/Frame 043537/0945 →